

## **Amendments to the Claims**

Claims 1-40 (canceled)

41. (new) A pharmaceutical composition comprising a pharmaceutically-acceptable carrier and a therapeutically effective amount of *N*-{2-[4-(3-phenyl-4-methoxyphenyl)aminophenyl]ethyl}-(*R*)-2-hydroxy-2-(8-hydroxy-2(1*H*)-quinolinon-5-yl)ethylamine or a pharmaceutically-acceptable salt thereof.

42. (new) The pharmaceutical composition of Claim 41, wherein the composition is formulated for administration by inhalation.

43. (new) The pharmaceutical composition of Claim 41 wherein the composition further comprises a therapeutically effective amount of a steroidal anti-inflammatory agent.

44. (new) The pharmaceutical composition of Claim 43, wherein the composition is formulated for administration by inhalation.

45. (new) The pharmaceutical composition of Claim 41, wherein the composition further comprises a therapeutically effective amount of one or more therapeutic agents selected from the group consisting of a steroidal anti-inflammatory agent, a muscarinic receptor antagonist agent, a phosphodiesterase inhibitor agent, an immunoglobulin antibody, a leukotriene antagonist agent, a cytokine antagonist agent, a protease inhibitor, cromolyn sodium, nedocromil sodium, and sodium cromoglycate.

46. (new) A method of treating a disease or condition in a mammal associated with  $\beta_2$  adrenergic receptor activity, the method comprising administering to the mammal, a therapeutically effective amount of a pharmaceutical composition of Claim 41.

47. (new) The method of Claim 46 wherein the disease or condition is a pulmonary disease.

48. (new) The method of Claim 47 wherein the pulmonary disease is asthma or chronic obstructive pulmonary disease.

49. (new) The method of Claim 46 wherein the disease or condition is selected from the group consisting of pre-term labor, neurological disorders, cardiac disorders, and inflammation.

50. (new) The method of Claim 46 further comprising administering a therapeutically effective amount of a steroidal anti-inflammatory agent.

51. (new) The method of Claim 46 further comprising administering a therapeutically effective amount of one or more therapeutic agents selected from the group consisting of a steroidal anti-inflammatory agent, a muscarinic receptor antagonist agent, a phosphodiesterase inhibitor agent, an immunoglobulin antibody, a leukotriene antagonist agent, a cytokine antagonist agent, a protease inhibitor, cromolyn sodium, nedocromil sodium, and sodium cromoglycate.